Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
This is a prospective, single-arm trial. The main purpose of the study is to evaluate the efficacy and safety of Nimotuzumab combined with nab-paclitaxel+ gemcitabine (AG regimen) for postoperative adjuvant treatment of pancreatic cancer with EGFR-positive.
Pancreatic Cancer Resectable
DRUG: Nimotuzumab|DRUG: AG
disease-free survival (DFS), The time from the date of surgery to the disease recurrence or death, whichever is earlier., Up to 24 months
distant metastasis-free survival (DMFS), The time from the date of surgery to the first distant metastasis or death due to any cause, whichever is earlier., Up to 24 months|overall survival (OS), The time from the date of surgery to death due to any cause., Up to 24 months|tumor-related markers, To explore the influence of tumor-related markers (such as KRAS gene, CDX-2 protein, etc.) on prognosis., Up to 24 months|adverse events, Frequency and severity of adverse events., Up to 30 days after last administration
This clinical study is designed as a prospective, open-label, single arm, phase II study to evaluate the clinical efficacy and safety of Nimotuzumab combined with AG (nab-paclitaxel+ gemcitabine) as postoperative adjuvant therapy in patients with EGFR-positive pancreatic cancer. The main endpoint is disease-free survival (DFS). Additional end points included distant metastasis-free survival (DMFS), overall survival (OS), tumor-related markers and safety.